ArticleJournal of asthma and allergy2026
Salbutamol Reversal of Methacholine Induced Bronchoconstriction: Vibrating Mesh Nebulizer versus Pressurized Metered Dose Inhaler.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reversal of methacholine induced bronchoconstriction (MIB) is routinely achieved by administering 200 mcg salbutamol via pressurized metered dose inhaler (pMDI). The propellant in the inhaler (hydrofluoroalkane-134a) contributes to greenhouse gas emissions, negatively impacting the environment. One alternative to delivering bronchodilator would be using the Aerogen Methods: Sixteen individuals exhibiting airway hyperresponsiveness to methacholine completed a double blind, double dummy, placebo controlled, randomized, three-way crossover study. At each visit, participants underwent MCT followed by administration of placebo or salbutamol (200 mcg) via pMDI or VMN. Lung function and heart rate measurements were captured before and at 5, 10, 15, 30, 45 and 60 minutes after treatment administration. Results: Pre MCT FEV Conclusion: Use of the VMN for delivering salbutamol to reverse MIB is feasible. Doing so adds functionality to the use of this nebulizer for performing methacholine bronchoprovocation and reduces the negative environmental impact of pMDI inhalers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.